An experimental strategy pushes drug-resistant stem cells into a susceptible state—and kills them. Download and Read “Luring Melanoma Cells totheir_Death.pdf"
MRV Research
Studies Support MEK Inhibitor for BRAF-Positive Melanoma
Adding a MEK inhibitor to a BRAF inhibitor substantially improves outcome in patients with BRAF mutation–positive advanced melanoma, according to two large Phase III studies presented at the European Society for Medical Oncology (ESMO) 2014 Congress. The results of the two studies, although using different types of BRAF and MEK inhibitors, were considered mutually reinforcing.
TERT Promoter Mutations Common in Melanoma
A recent study has confirmed that TERT promoter mutations are common genetic mutations in cutaneous melanoma, and that these mutations may be linked with poor prognosis in certain subtypes of the disease.
FDA Expands Approval of Lymphoseek to Breast Cancer and Melanoma
The FDA has expanded the approval of Lymphoseek (technetium Tc 99m tilmanocept) injection to include lymphatic mapping in solid tumors and sentinel lymph node (SLN) detection for breast cancer and melanoma, according to Navidea Biopharmaceuticals, Inc. Additionally, the FDA has also approved the use of Lymphoseek with or without scintigraphic imaging for pre-operative mapping of lymph nodes, aimed to facilitate node localization during surgical procedures.